Enanta Pharmaceuticals Q2 Royalty Revenue $17.16M; Net Loss Narrows
Enanta Pharmaceuticals reported a significant narrowing of its net loss for the second quarter of fiscal year 2026, with royalty revenue increasing. The company's net loss improved to $13.09 million, or $(0.45) per share, compared to $22.64 million, or $(1.06) per share, in the prior year. This improvement was supported by a 15% increase in royalty revenue to $17.16 million and a 31% reduction in R&D expenses. Additionally, the company completed a public offering in October 2025, raising $74.75 million, which contributed to an 80% increase in total stockholders' equity. The company also provided updates on its ongoing patent infringement litigation against Pfizer, including an appeal in the U.S. and a new action in the EU.
Key Highlights
- Q2 2026 royalty revenue increased 15% to $17.16 million.
- Q2 2026 net loss narrowed 42% to $13.09 million, or $(0.45) per share.
- R&D expenses decreased 31% to $19.44 million in Q2 2026.
- October 2025 public offering raised $74.75 million gross.
- Total stockholders' equity grew 80% to $116.59 million.
- Net cash used in operating activities improved to $(18.86) million.
- Appeal oral argument held May 11, 2026, in Pfizer patent suit.
- Filed new patent infringement action in EU against Pfizer.
Price Impact
More from ENTA